Table of Contents PART 01: Executive summary PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Highlights PART 05: Disease overview • Understanding the disease • Pathophysiology • Central pathway • Peripheral pathway • Management of disease PART 06: Pipeline analysis PART 07: Market landscape • Global CINV drugs market • Five forces analysis PART 08: Market segmentation by therapy • Serotonin receptor antagonists • NK1 receptor antoagonists • Others PART 09: Geographical segmentation • CINV drugs market in Americas • CINV drugs market in EMEA • CINV drugs market in APAC PART 10: Market drivers • Growing cancer population driving the market growth • Growing preference for chemotherapy drugs in developing countries • Approval of new drugs fuels the market growth PART 11: Impact of drivers PART 12: Market challenges • Growing popularity of alternate therapies for the treatment of cancer in developed countries • Loss of patent exclusivities increasing generic competition • Limitations in existing therapies hindering the growth prospects PART 13: Impact of drivers and challenges PART 14: Market trends • Robust R&D activities fueling the pipeline • Increasing inorganic growth strategies likely to fuel the market growth • Novel treatment options coupled with new applications PART 15: Vendor landscape • Competitive scenario PART 16: Key vendor analysis • GlaxoSmithKline • Helsinn • Heron Therapeutics • Merck • Tesaro • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Pipeline landscape Exhibit 03: Key pipeline candidates Exhibit 04: Global CINV drugs market snapshot Exhibit 05: Analysis of global CINV drugs market Exhibit 06: Global CINV drugs market 2016-2021 ($ billions) Exhibit 07: Key initiatives in emerging economies Exhibit 08: Opportunity analysis of global CINV drugs market Exhibit 09: Opportunity analysis in developed and emerging markets Exhibit 10: Five forces analysis Exhibit 11: Segmentation of global CINV drugs market by therapy 2016 (% share) Exhibit 12: Lifecycle analysis of segments in global CINV drugs market Exhibit 13: Geographic segmentation by revenue 2016 and 2021 Exhibit 14: Geographic segmentation by revenue 2016 ($ millions) Exhibit 15: Market scenario in Americas Exhibit 16: CINV drugs market in Americas 2016-2021 ($ millions) Exhibit 17: Market scenario in EMEA Exhibit 18: CINV drugs market in EMEA 2016-2021 ($ millions) Exhibit 19: Market scenario in APAC Exhibit 20: CINV drugs market in APAC 2016-2021 ($ millions) Exhibit 21: Key drivers and challenges in APAC Exhibit 22: Top ten cancers in the US in 2013 Exhibit 23: Key approvals in the market in 2015 and 2016 Exhibit 24: Impact of drivers Exhibit 25: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions) Exhibit 26: Forcefield analysis of drivers and challenges Exhibit 27: Impact of drivers and challenges Exhibit 28: Key vendors that are extensively conducting R&D activities Exhibit 29: Competitive structure analysis of global CINV drugs market 2015 Exhibit 30: Market share analysis in global CINV drugs market Exhibit 31: Competitive analysis of global CINV drugs market Exhibit 32: Market penetration of various global CINV drugs manufacturers 2015 Exhibit 33: GlaxoSmithKline: Strength assessment Exhibit 34: GlaxoSmithKline: Strategy assessment Exhibit 35: GlaxoSmithKline: Opportunity assessment Exhibit 36: Helsinn: Key highlights Exhibit 37: Helsinn: Strength assessment Exhibit 38: Helsinn: Strategy assessment Exhibit 39: Helsinn: Opportunity assessment Exhibit 40: Heron Therapeutics: Key highlights Exhibit 41: Heron Therapeutics: Strength assessment Exhibit 42: Heron Therapeutics strategy assessment Exhibit 43: Heron Therapeutics: Opportunity assessment Exhibit 44: Merck: Key highlights Exhibit 45: Merck: strength assessment Exhibit 46: Merck: Strategy assessment Exhibit 47: Merck: Opportunity assessment Exhibit 48: Merck: YoY revenue and growth rate of EMEND 2013-2015 ($ millions) Exhibit 49: Tesaro: Key highlights Exhibit 50: Tesaro: Strength assessment Exhibit 51: Tesaro: Strategy assessment Exhibit 52: Tesaro: Opportunity assessment

GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, Acacia Pharma, Aphios, Baxter Healthcare, Dr. Reddy's Laboratories, Eisai, Especificos Stendhal, F. Hoffmann-La Roche, Kyowa Hakko Kirin, Lee’s Pharmaceutical Holdings, Midatech Pharma, Mundipharma, Mylan, Ono Pharmaceutical, OPKO Health, Orchid Chemicals & Pharmaceuticals, Otsuka Pharmaceutical, Purdue Pharma, Sandoz (a subsidiary of Novartis), SciClone Pharmaceuticals, Shin Nippon Biomedical Laboratories, Solasia Pharma K.K., Specialised Therapeutics, Sun Pharma, Taiho Pharmaceutical, Teva Pharmaceuticals.